ω-Substituted alkyl carboxylic acids as antidiabetic and lipid-lowering agents

被引:10
|
作者
Meyer, K
Voss, E
Neidlein, R
Kühnle, HF
Pill, J
机构
[1] Boehringer Mannheim GmbH, Therapeut Res, D-6800 Mannheim, Germany
[2] Univ Heidelberg, Inst Pharmazeut Chem, D-6900 Heidelberg, Germany
关键词
omega-substituted alkyl carboxylic acids; insulin sensitizer; lipid lowering;
D O I
10.1016/S0223-5234(99)80029-4
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In screening experiments certain omega-substituted alkyl carboxylic acids were found to produce an increase in insulin-stimulated C-14-acetate incorporation into triglycerides, which may indicate an improvement in the action of insulin. Antidiabetic and lipid-lowering properties in genetically diabetic ob/ob mice demonstrated the in vivo relevance of the insulin-potentiating effects seen in vitro. The chemical structures of the w-substituted alkyl carboxylic acids with insulin-potentiating effects correspond to the general formula ring-spacer-COOH. A close structure-activity relationship was observed. The most potent compound in ob/ob mice was 3e, which normalized blood glucose as well as hyperinsulinaemia and lowered serum triglycerides and cholesterol by 52% and 37%, respectively. On the basis of these results, omega-substituted alkyl carboxylic acids are interesting as a new class of oral antidiabetic agents with insulin-sensitizing and lipid-lowering activity. (C) Elsevier, Paris.
引用
收藏
页码:775 / 787
页数:13
相关论文
共 50 条
  • [21] Myopathies under therapy with lipid-lowering agents
    Köller, H
    Neuhaus, O
    Schroeter, M
    Hartung, H
    NERVENARZT, 2005, 76 (02): : 212 - 217
  • [22] FLUVASTATIN IN COMBINATION WITH OTHER LIPID-LOWERING AGENTS
    JOKUBAITIS, LA
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1994, : 28 - 32
  • [23] Lipid-lowering agents and cognitive decline in AD
    Christine Kyme
    Nature Clinical Practice Neurology, 2006, 2 (3): : 121 - 122
  • [24] Xanthoma disseminatum treated with lipid-lowering agents
    Michelle Doria-Perez, Karla
    Alfredo Soto-Ortiz, Jose
    Berenice Matildes-Mariscal, Jessica
    Gabriel Barrientos-Garcia, Juan
    Javier Salazar-Torres, Francisco
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB314 - AB314
  • [25] Hepatotoxicity of statins and other lipid-lowering agents
    Bjornsson, Einar S.
    LIVER INTERNATIONAL, 2017, 37 (02) : 173 - 178
  • [26] Re: Lipid-lowering agents and risk of melanoma
    Friis, S
    INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (02) : 334 - 334
  • [27] Lipid levels and the use of lipid-lowering agents in England and Scotland
    Primatesta, P
    Poulter, NR
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2004, 11 (06): : 484 - 488
  • [28] Use of lipid-lowering agents (statins) during pregnancy
    Hosokawa, A
    Bar-Oz, B
    Ito, S
    CANADIAN FAMILY PHYSICIAN, 2003, 49 : 747 - 749
  • [29] Lipid-lowering agents for preventing melanoma: An ongoing review
    Dellavalle, RP
    Drake, A
    Graber, M
    McNealy, K
    Morelli, J
    Schilling, LM
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1317S - 1317S
  • [30] CUTANEOUS SIDE-EFFECTS OF LIPID-LOWERING AGENTS
    PROKSCH, E
    HAUTARZT, 1995, 46 (02): : 76 - 80